VireturnRevenue
14.3B USDAnnual · FY 2025REGN
REGENERON PHARMACEUTICALS, INC.
Operating income
3.6B USDAnnual · FY 2025Net income
4.5B USDAnnual · FY 2025Total assets
40.6B USDAnnual · FY 2025Equity
31.3B USDAnnual · FY 2025Operating cash flow
5B USDAnnual · FY 2025REGN · Chart
Chart provided by TradingView. Loading the chart connects your browser to TradingView and sends necessary technical information such as your IP address, page URL, and displayed symbol.
Reported financial information
Revenue
USD
14.3B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 16.1B USD |
| FY 2022 | 12.2B USD |
| FY 2023 | 13.1B USD |
| FY 2024 | 14.2B USD |
| FY 2025 | 14.3B USD |
Operating income
USD
3.6B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 8.9B USD |
| FY 2022 | 4.7B USD |
| FY 2023 | 4B USD |
| FY 2024 | 4B USD |
| FY 2025 | 3.6B USD |
Net income
USD
4.5B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 8.1B USD |
| FY 2022 | 4.3B USD |
| FY 2023 | 4B USD |
| FY 2024 | 4.4B USD |
| FY 2025 | 4.5B USD |
Total assets
USD
40.6B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 25.4B USD |
| FY 2022 | 29.2B USD |
| FY 2023 | 33.1B USD |
| FY 2024 | 37.8B USD |
| FY 2025 | 40.6B USD |
Equity
USD
31.3B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 18.8B USD |
| FY 2022 | 22.7B USD |
| FY 2023 | 26B USD |
| FY 2024 | 29.4B USD |
| FY 2025 | 31.3B USD |
Operating cash flow
USD
5B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 7.1B USD |
| FY 2022 | 5B USD |
| FY 2023 | 4.6B USD |
| FY 2024 | 4.4B USD |
| FY 2025 | 5B USD |
Revenue growth
%
1%
Period data
| Period | Value |
|---|---|
| FY 2021 | 89.1% |
| FY 2022 | -24.3% |
| FY 2023 | 7.8% |
| FY 2024 | 8.3% |
| FY 2025 | 1% |
Operating income growth
%
-10.3%
Period data
| Period | Value |
|---|---|
| FY 2021 | 150.1% |
| FY 2022 | -47% |
| FY 2023 | -14.6% |
| FY 2024 | -1.4% |
| FY 2025 | -10.3% |
Net income growth
%
2.1%
Period data
| Period | Value |
|---|---|
| FY 2021 | 129.9% |
| FY 2022 | -46.3% |
| FY 2023 | -8.9% |
| FY 2024 | 11.6% |
| FY 2025 | 2.1% |
Operating margin
%
24.9%
Period data
| Period | Value |
|---|---|
| FY 2021 | 55.7% |
| FY 2022 | 38.9% |
| FY 2023 | 30.9% |
| FY 2024 | 28.1% |
| FY 2025 | 24.9% |
Net margin
%
31.4%
Period data
| Period | Value |
|---|---|
| FY 2021 | 50.2% |
| FY 2022 | 35.6% |
| FY 2023 | 30.1% |
| FY 2024 | 31.1% |
| FY 2025 | 31.4% |
Return on assets
%
11.5%
Period data
| Period | Value |
|---|---|
| FY 2021 | 37.9% |
| FY 2022 | 15.9% |
| FY 2023 | 12.7% |
| FY 2024 | 12.5% |
| FY 2025 | 11.5% |
Debt/Equity
x
0.3x
Period data
| Period | Value |
|---|---|
| FY 2021 | 0.36x |
| FY 2022 | 0.29x |
| FY 2023 | 0.27x |
| FY 2024 | 0.29x |
| FY 2025 | 0.3x |